Drug Trial Radar · NCT04971226
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
405
Actual
Start
Oct 6, 2021
Primary completion
Nov 28, 2023
Study completion Jan 18, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected Tyrosine Kinase Inhibitor (TKI) for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP. The Investigator selected TKI will be one of the following treatment options for first-line treatment of CML-CP - imatinib 400 mg QD or nilotinib 300 mg BID or dasatinib 100 mg QD or bosutinib 400 mg QD. This study has three periods: 1. Treatment period for all randomized participants, 2. Optional Treatment-Free Remission (TFR) period only for participants meeting TFR eligibility criteria and 3. Treatment Re-Initiation (TRI) period only for participants who relapsed after TFR attempt.
Conditions
- Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Interventions
ImatinibDrug
Comes in 100 mg and 400 mg tablets and taken orally
NilotinibDrug
Comes in 150 mg and 200 mg capsules and taken orally
BosutinibDrug
Comes in 100 mg and 400 mg tablets and taken orally
DasatinibDrug
Comes in 20 mg, 50 mg, 70 mg and 100 mg tablets and taken orally
AsciminibDrug
Comes in 40 mg tablets and taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKITime frame: At 48 weeks
- Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Asciminib (Imatinib Stratum) vs Investigator Selected TKI (Imatinib Stratum)Time frame: At 48 weeks
Locations
110 sites in 29 countries. Site status is shown where the registry gives one.
Rocky Mountain Cancer Centers
Denver, Colorado
Florida Cancer Specialists
Fort Myers, Florida
Florida Cancer Specialists Pan
Tallahassee, Florida
University of Kentucky
Lexington, Kentucky
Uni of Massachusetts Medical Center
Worcester, Massachusetts
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina
Williamette Cancer Center
Eugene, Oregon
Oregon Health Sciences University
Portland, Oregon
Avera Cancer
Sioux Falls, South Dakota
Chattanooga Onc And Hem Assoc PC
Chattanooga, Tennessee
Texas Oncology
Amarillo, Texas
Texas Oncology-Baylor USO
Dallas, Texas
Texas Oncology
Dallas, Texas
Novartis Investigative Site
Southport, Australia
Novartis Investigative Site
Kingswood, New South Wales, Australia
Novartis Investigative Site
Port Macquarie, New South Wales, Australia
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Linz, Upper Austria, Austria
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Leuven, Vlaams Brabant, Belgium
Novartis Investigative Site
Varna, Bulgaria
Novartis Investigative Site
Calgary, Alberta, Canada
Novartis Investigative Site
Hamilton, Ontario, Canada
Novartis Investigative Site
Ottawa, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Lanzhou, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Shenzhen, Guangdong, China
Novartis Investigative Site
Zhengzhou, Henan, China
Novartis Investigative Site
Wuhan, Hubei, China
Novartis Investigative Site
Nanjing, Jiangsu, China
Novartis Investigative Site
Suzhou, Jiangsu, China
Novartis Investigative Site
Xian, Shanxi, China
Novartis Investigative Site
Chengdu, Sichuan, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Wenzhou, Zhejiang, China
Novartis Investigative Site
Brno, Czechia
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.